SAB Biotherapeutics Valuation
| SABS Stock | USD 3.51 0.24 7.34% |
At this time, the entity appears to be overvalued. SAB Biotherapeutics owns a latest Real Value of $2.85 per share. The recent price of the entity is $3.51. Our model measures the value of SAB Biotherapeutics from examining the entity fundamentals such as Return On Asset of -0.59, shares owned by institutions of 35.00 %, and Current Valuation of 411.42 K as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting SAB Biotherapeutics' valuation include:
Price Book 0.7024 | Enterprise Value 411.4 K | Enterprise Value Ebitda (1.49) | Price Sales 11.6524 | Enterprise Value Revenue 1.206 |
Overvalued
Today
Please note that SAB Biotherapeutics' price fluctuation is dangerous at this time. Calculation of the real value of SAB Biotherapeutics is based on 3 months time horizon. Increasing SAB Biotherapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the SAB stock is determined by what a typical buyer is willing to pay for full or partial control of SAB Biotherapeutics. Since SAB Biotherapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of SAB Stock. However, SAB Biotherapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.51 | Real 2.85 | Target 2.3 | Hype 3.51 |
The intrinsic value of SAB Biotherapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence SAB Biotherapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of SAB Biotherapeutics helps investors to forecast how SAB stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of SAB Biotherapeutics more accurately as focusing exclusively on SAB Biotherapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use SAB Biotherapeutics' intrinsic value based on its ongoing forecasts of SAB Biotherapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against SAB Biotherapeutics' closest peers.
SAB Biotherapeutics Cash |
|
SAB Valuation Trend
SAB Biotherapeutics' real value is important for investors to make better decisions and a more accurate overall view of SAB Biotherapeutics' financial worth over time. Using both SAB Biotherapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
SAB Biotherapeutics Total Value Analysis
SAB Biotherapeutics is at this time forecasted to have valuation of 411.42 K with market capitalization of 32.39 M, debt of 5.91 M, and cash on hands of 16.62 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the SAB Biotherapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
411.42 K | 32.39 M | 5.91 M | 16.62 M |
SAB Biotherapeutics Investor Information
About 19.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.7. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. SAB Biotherapeutics recorded a loss per share of 6.16. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 5th of January 2024. Based on the key indicators related to SAB Biotherapeutics' liquidity, profitability, solvency, and operating efficiency, SAB Biotherapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.SAB Biotherapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. SAB Biotherapeutics has an asset utilization ratio of 2.67 percent. This implies that the Company is making $0.0267 for each dollar of assets. An increasing asset utilization means that SAB Biotherapeutics is more efficient with each dollar of assets it utilizes for everyday operations.SAB Biotherapeutics Ownership Allocation
The market capitalization of SAB Biotherapeutics is $32.39 Million. 30% of SAB Biotherapeutics outstanding shares are owned by institutions. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Thereupon, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the entity is larger than the current market value, you may still be able to generate positive returns on investment in this company.SAB Biotherapeutics Profitability Analysis
The company reported the previous year's revenue of 2.24 M. Net Loss for the year was (42.19 M) with loss before overhead, payroll, taxes, and interest of (12.53 M).About SAB Biotherapeutics Valuation
The stock valuation mechanism determines SAB Biotherapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of SAB Biotherapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of SAB Biotherapeutics. We calculate exposure to SAB Biotherapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of SAB Biotherapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -1.5 M | -1.4 M | |
| Pretax Profit Margin | (18.85) | (17.90) | |
| Operating Profit Margin | (17.01) | (16.16) | |
| Net Loss | (18.85) | (17.90) | |
| Gross Profit Margin | (0.67) | (0.64) |
SAB Biotherapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as SAB Biotherapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 5.5 M | |
| Quarterly Earnings Growth Y O Y | -0.6 |
SAB Biotherapeutics Current Valuation Indicators
SAB Biotherapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final SAB Biotherapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as SAB Biotherapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use SAB Biotherapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes SAB Biotherapeutics' worth.Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.